The global GLP-1 analogues market, valued at US$37.4 billion in 2023, is forecasted to grow at a robust CAGR of 33.2%, reaching US$47.4 billion in 2024 and an impressive US$471.1 billion by 2032. The comprehensive research encompasses an exhaustive examination of industry trends, meticulous pricing analysis, patent scrutiny, insights derived from conferences and webinars, identification of key stakeholders, and a nuanced understanding of market purchasing dynamics. GLP-1 analogue drugs have gained high acceptance in recent years, especially after their benefits in treating chronic obesity and weight management became known widely. In addition, the clinical pipeline for this drug class is strong. The pipeline reveals an abundance of products (existing and innovative molecules) expected to launch during the forecast period. A few notable product instances include- Oral semaglutide (25 mg and 50 mg) for type 2 diabetes, CagriSema (a combination product of Cagrilintide and Semaglutide) for obesity as well as type 2 diabetes, Survodutide for the treatment of obesity and Nonalcoholic steatohepatitis (NASH), Semaglutide against NASH, and among others. Thus, this is a key factor driving market growth. However, more than 90% of the marketed products are offered by two key players in the market- Novo Nordisk A/S and Eli Lilly and Company. This has created a duopoly in the market. This factor thus, is expected to create high entry barriers for new entrants in the market.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=218746186
Browse in-depth TOC on “GLP-1 Analogues Market“.
405 – Tables59 – Figures315 – Pages
Ozempic Leads the Charge in the GLP-1 Analogue Market
In 2023, Ozempic (semaglutide) dominated the GLP-1 Analogue market, buoyed by its significant revenue contribution and broad global application for diabetes treatment. Its market presence extends to obesity treatment under the brand Wegovy in Brazil, with a notable growth rate of approximately 70% from 2019 to 2023. Such robust performance underscores Ozempic’s pivotal role in driving market expansion throughout the forecast period.
Single-Dose Formats Propel Growth in GLP-1 Analogue Adoption
The single-dose segment held the largest share of the GLP-1 Analogue market in 2023, a trend expected to persist. This dominance is attributed to the convenience and enhanced adherence facilitated by products like WEGOVY and TRULICITY, which offer comfortable weekly self-administration via autoinjectors. These advantages are set to bolster the segment’s growth moving forward.
Subcutaneous Administration Commands Market Preference
In 2023, subcutaneous administration accounted for the largest market share in the GLP-1 Analogue segment, leveraging its ability to bypass gastrointestinal adverse effects and deliver rapid therapeutic effects. This preference is bolstered by the availability of diverse injector types, including pen injectors and autoinjectors, catering to varied patient needs.
Diabetes Indication Spearheads GLP-1 Analogue Market
The diabetes indication segment emerged as the largest in the GLP-1 Analogue market in 2023, driven by increasing demand for effective Type-2 Diabetes management. This growth is further supported by a robust research and development pipeline focusing on enhancing therapeutic outcomes compared to other antidiabetic drug classes.
Home Care Settings Drive GLP-1 Analogue Adoption
Home care settings dominated the GLP-1 Analogue market in 2023, facilitated by the convenience and patient adherence advantages offered by at-home drug administration. This trend is augmented by the expanding utilization of GLP-1 Analogue drugs in treating obesity outside traditional healthcare facilities.
North America Poised for Significant Growth in GLP-1 Analogue Market
North America, particularly the US, is expected to exhibit the highest growth rate in the GLP-1 Analogue market during the forecast period. This projection stems from increasing adoption of GLP-1 drugs for diabetes and obesity treatment, supported by well-established healthcare infrastructure and favorable reimbursement frameworks.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=218746186
Novo Nordisk A/S (Denmark) is an established playerin this market. The company contributes significantly to the GLP-1 Analogue market. The company has a strong product portfolio, robust brand recognition, and geographic presence with distribution channels across the globe. The company has a focused approach towards the development of antidiabetic therapeutic products. The major revenue-generating GLP-1 Analogue drugs include ozempic and wegovy. The strong manufacturing ecosystem of the company makes it the largest manufacturer of insulin and GLP-1 globally. The company also has a wide range of potential therapeutic products in the clinical pipeline. Novo Nordisk also focuses on developing oral forms of its existing GLP-1 drugs, like semaglutide, making it more convenient for patients.
Eli Lilly and Company (US) is another key player in the GLP-1 Analogues market. The company has a strong focus on expanding its research and development pipeline in all phases of clinical development. The company invested ~USD 9 billion in R&D in 2023. The company leverages business development activities to strengthen its market position in the GLP-1 Analogues market. The company has three commercialized GLP-1 Analogues class drugs: Mounjaro, Trulicity, and Zepbound. These drugs bring in high revenue for the company, with Trulicity and Mounjaro accounting for ~36% of the company’s revenue in 2023.
Sanofi (France) is also a well-established player in the GLP-1 Analogue market. The company has one commercialized GLP-1 analogue drug, Soliqua. The major strengths of the company are a strong geographical presence and a wide customer base. For instance, the company markets its GLP-1 analogue drug, Soliqua in more than 80 countries and is constantly acquiring regulatory approvals for its GLP-1 products across different geographies. For example, in January 2023, the company received approval for its GLP-1 Analogue drug Soliqua, in China for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycemic control as an adjunct to diet, exercise, and other oral antidiabetic drugs. Additionally, in December 2023, SOLIQUA received National Reimbursement Drug List (NRDL) status in China.
For more information, inquire now! Inquire Now
Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/glp-1-analogues-market-218746186.html